Anhui Huangshan Capsule Co Ltd
Anhui Huangshan Capsule Co., Ltd. engages in the research and development, production, and sale of gelatin and enteric-coated gelatin empty capsules in China. It offers hypromellose empty capsules, pullulan empty capsules, entersoluble vacant gelatin capsules, vacant gelatin capsules, vegetable entersoluble capsules, colonsoluble vacant gelatin capsules, hydroxypropyl methyl cellulose hollow caps… Read more
Anhui Huangshan Capsule Co Ltd (002817) - Net Assets
Latest net assets as of September 2025: CN¥956.01 Million CNY
Based on the latest financial reports, Anhui Huangshan Capsule Co Ltd (002817) has net assets worth CN¥956.01 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.11 Billion) and total liabilities (CN¥156.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥956.01 Million |
| % of Total Assets | 85.9% |
| Annual Growth Rate | 14.98% |
| 5-Year Change | 19.95% |
| 10-Year Change | 183.33% |
| Growth Volatility | 24.0 |
Anhui Huangshan Capsule Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Anhui Huangshan Capsule Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anhui Huangshan Capsule Co Ltd (2011–2024)
The table below shows the annual net assets of Anhui Huangshan Capsule Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥917.76 Million | +1.85% |
| 2023-12-31 | CN¥901.11 Million | +5.49% |
| 2022-12-31 | CN¥854.21 Million | +5.46% |
| 2021-12-31 | CN¥809.98 Million | +5.86% |
| 2020-12-31 | CN¥765.15 Million | +5.35% |
| 2019-12-31 | CN¥726.33 Million | +4.27% |
| 2018-12-31 | CN¥696.59 Million | +4.58% |
| 2017-12-31 | CN¥666.10 Million | +5.57% |
| 2016-12-31 | CN¥630.95 Million | +94.79% |
| 2015-12-31 | CN¥323.92 Million | +16.19% |
| 2014-12-31 | CN¥278.78 Million | +17.74% |
| 2013-12-31 | CN¥236.77 Million | +19.96% |
| 2012-12-31 | CN¥197.36 Million | +32.08% |
| 2011-12-31 | CN¥149.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anhui Huangshan Capsule Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1576.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥462.69 Million | 50.49% |
| Common Stock | CN¥299.10 Million | 32.64% |
| Other Comprehensive Income | CN¥69.50 Million | 7.58% |
| Other Components | CN¥85.15 Million | 9.29% |
| Total Equity | CN¥916.44 Million | 100.00% |
Anhui Huangshan Capsule Co Ltd Competitors by Market Cap
The table below lists competitors of Anhui Huangshan Capsule Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunteck Realty Limited
NSE:SUNTECK
|
$196.92 Million |
|
Qingdao Vland Biotech Co Ltd
SHG:603739
|
$196.98 Million |
|
Ta Ann Holdings Bhd
KLSE:5012
|
$197.01 Million |
|
Concord International Securities Co Ltd
TWO:5864
|
$197.05 Million |
|
VITZROCELL Co.Ltd
KQ:082920
|
$196.85 Million |
|
CPH Chemie und Papier Holding
SW:CPHN
|
$196.83 Million |
|
Shandong Donghong Pipe Ind Co
SHG:603856
|
$196.76 Million |
|
Wildcat Resources Ltd
AU:WC8
|
$196.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anhui Huangshan Capsule Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 900,478,351 to 916,439,508, a change of 15,961,157 (1.8%).
- Net income of 49,253,369 contributed positively to equity growth.
- Dividend payments of 25,684,907 reduced retained earnings.
- Other comprehensive income increased equity by 68,978,456.
- Other factors decreased equity by 76,585,761.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥49.25 Million | +5.37% |
| Dividends Paid | CN¥25.68 Million | -2.8% |
| Other Comprehensive Income | CN¥68.98 Million | +7.53% |
| Other Changes | CN¥-76.59 Million | -8.36% |
| Total Change | CN¥- | 1.77% |
Book Value vs Market Value Analysis
This analysis compares Anhui Huangshan Capsule Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.45x to 2.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.67 | CN¥8.32 | x |
| 2012-12-31 | CN¥0.88 | CN¥8.32 | x |
| 2013-12-31 | CN¥1.06 | CN¥8.32 | x |
| 2014-12-31 | CN¥1.25 | CN¥8.32 | x |
| 2015-12-31 | CN¥1.44 | CN¥8.32 | x |
| 2016-12-31 | CN¥2.66 | CN¥8.32 | x |
| 2017-12-31 | CN¥2.25 | CN¥8.32 | x |
| 2018-12-31 | CN¥2.29 | CN¥8.32 | x |
| 2019-12-31 | CN¥2.42 | CN¥8.32 | x |
| 2020-12-31 | CN¥2.55 | CN¥8.32 | x |
| 2021-12-31 | CN¥3.62 | CN¥8.32 | x |
| 2022-12-31 | CN¥2.85 | CN¥8.32 | x |
| 2023-12-31 | CN¥3.05 | CN¥8.32 | x |
| 2024-12-31 | CN¥3.06 | CN¥8.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anhui Huangshan Capsule Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.37%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.40%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.19x
- Recent ROE (5.37%) is below the historical average (11.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 24.99% | 19.71% | 0.96x | 1.33x | CN¥22.40 Million |
| 2012 | 24.29% | 19.65% | 0.92x | 1.34x | CN¥28.20 Million |
| 2013 | 20.27% | 17.84% | 0.82x | 1.38x | CN¥24.31 Million |
| 2014 | 18.57% | 18.93% | 0.78x | 1.26x | CN¥23.88 Million |
| 2015 | 16.95% | 21.63% | 0.61x | 1.28x | CN¥22.50 Million |
| 2016 | 8.29% | 18.45% | 0.41x | 1.11x | CN¥-10.81 Million |
| 2017 | 6.97% | 16.23% | 0.39x | 1.11x | CN¥-20.19 Million |
| 2018 | 5.19% | 12.20% | 0.38x | 1.13x | CN¥-33.29 Million |
| 2019 | 5.40% | 12.02% | 0.39x | 1.15x | CN¥-33.33 Million |
| 2020 | 5.94% | 14.17% | 0.35x | 1.20x | CN¥-30.92 Million |
| 2021 | 7.03% | 14.97% | 0.36x | 1.30x | CN¥-24.08 Million |
| 2022 | 7.13% | 14.21% | 0.41x | 1.22x | CN¥-24.53 Million |
| 2023 | 7.20% | 14.02% | 0.42x | 1.22x | CN¥-25.18 Million |
| 2024 | 5.37% | 10.40% | 0.44x | 1.19x | CN¥-42.39 Million |
Industry Comparison
This section compares Anhui Huangshan Capsule Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anhui Huangshan Capsule Co Ltd (002817) | CN¥956.01 Million | 24.99% | 0.16x | $196.91 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |